We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current NUZ market cap is 43.45M. The company's latest EPS is AUD -0.0194 and P/E is -5.67.
| Year End June 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Revenue | 4.12M | 3.66M | 4.51M | 3.82M | 924k |
| Operating Income | -1.25M | -1.27M | -1.62M | -5.58M | -9.06M |
| Net Income | -1.36M | -1.34M | -1.71M | -6.21M | -7.67M |
| Year End June 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Assets | 10.75M | 10.95M | 10.08M | 6.13M | 11.13M |
| Total Liabilities | 2.22M | 2.07M | 2.23M | 2.24M | 897k |
| Total Equity | 8.53M | 8.88M | 7.84M | 3.89M | 10.23M |
| Year End June 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Operating | -1.27M | -938k | -1.33M | -1.56M | -5.17M |
| Investing | -30k | -138k | -43k | -35k | -1.17M |
| Financing | 2.09M | 1.22M | 771k | 1.89M | 13.34M |
| Market Cap | 43.45M |
| Price to Earnings Ratio | -5.67 |
| Price to Sales Ratio | 47.83 |
| Price to Cash Ratio | 4.47 |
| Price to Book Ratio | 4.25 |
| Dividend Yield | - |
| Shares Outstanding | 395.01M |
| Average Volume (1 week) | 699.38k |
| Average Volume (1 Month) | 432.73k |
| 52 Week Change | -52.17% |
| 52 Week High | 0.245 |
| 52 Week Low | 0.096 |
| Spread (Intraday) | 0.01 (8.7%) |
| Company Name | Neurizon Therapeutics Ltd |
| Address |
level 4 melbourne, victoria 3205 |
| Website | https://www.neurizon.com/ |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
